**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a study of patients from the Columbia University kidney transplant program, USA, 15 patients (10 men and 5 women) aged 21−78 years were described, who developed coronavirus-2019 infection (COVID-19) during immunosuppressive treatment with belatacept, mycophenolic acid, prednisone, tacrolimus, mycophenolate mofetil, azathioprine, adalimumab or leflunomide \[*dosages, routes and duration of treatments to reactions onsets not stated; not all outcomes stated*\].

The patients were admitted with symptoms including fatigue, cough, fever, myalgia, dyspnoea, diarrhoea, exertional dyspnoea, fatigue, haemoptysis or emesis since 1 day to 3 weeks. They had undergone kidney transplantation, and had been receiving immunosuppressive treatment with belatacept, mycophenolic acid and prednisone (1 patient), tacrolimus, mycophenolate mofetil, mycophenolic acid and prednisone (1 patient), tacrolimus, azathioprine, adalimumab and prednisone (1 patient), tacrolimus, mycophenolate mofetil, prednisone and mycophenolic acid (1 patient), tacrolimus, mycophenolate mofetil and prednisone (1 patient), tacrolimus and mycophenolate mofetil (3 patients), belatacept, tacrolimus, mycophenolate mofetil and prednisone (1 patient), tacrolimus and mycophenolic acid (1 patient), tacrolimus, prednisone and mycophenolate mofetil (3 patients), tacrolimus and leflunomide (1 patient), and tacrolimus and prednisone (1 patient). Based on the chest X-ray and laboratory findings, the patients were diagnosed with COVID-19 infection. Subsequently, three of the 15 patients developed acute respiratory distress syndrome (ARDS).

The treatment with mycophenolic acid, mycophenolate mofetil, tacrolimus, azathioprine or leflunomide was interrupted in 14 of the 15 patients. Additionally, belatacept therapy was postponed in one patient. In the remaining one patient, the dose of prednisone and tacrolimus was reduced. Of the 15 patients, 13 patients were treated with off-label azithromycin and hydroxychloroquine (8 patients), azithromycin, hydroxychloroquine and tocilizumab (1 patient), and hydroxychloroquine (4 patients). Four patients required mechanical ventilation. Six of the 13 patients concomitantly developed acute kidney injury \[*aetiologies not stated*\]. After 5−7 days of symptoms onset, 4 of the 15 patients were intubated. Of the 15 patients, 8 patients were discharged with a favourable outcome, 2 patients remained admitted, 2 patients remained intubated, 1 patient was extubated and 2 patients died due to ARDS.
